MARKET

MBRX

MBRX

Moleculin Biotec
NASDAQ
4.120
+0.220
+5.64%
Closed 19:54 01/06 EST
OPEN
3.930
PREV CLOSE
3.900
HIGH
4.317
LOW
3.864
VOLUME
202.37K
TURNOVER
--
52 WEEK HIGH
91.25
52 WEEK LOW
3.130
MARKET CAP
11.10M
P/E (TTM)
-0.0737
1D
5D
1M
3M
1Y
5Y
1D
Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements
TipRanks · 6h ago
Moleculin Biotech Regains Nasdaq Listing Compliance; Delisting Hearing Canceled
Benzinga · 6h ago
MOLECULIN BIOTECH INC - REGAINS NASDAQ LISTING COMPLIANCE - SEC FILING
Reuters · 6h ago
Weekly Report: what happened at MBRX last week (1229-0102)?
Weekly Report · 2d ago
Weekly Report: what happened at MBRX last week (1222-1226)?
Weekly Report · 12/29/2025 10:13
Moleculin Biotech files to sell 2.61M shares of common stock for holders
TipRanks · 12/23/2025 21:50
Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (MBRX) and FibroBiologics, Inc. (FBLG)
TipRanks · 12/23/2025 12:50
Moleculin Biotech Amends Warrants to Boost Nasdaq Compliance
TipRanks · 12/22/2025 14:18
More
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Webull offers Moleculin Biotech Inc stock information, including NASDAQ: MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.